Vir Biotechnology Chief Medical Officer Mark Eisner to Step Down

On April 7, 2026, Vir Biotechnology, Inc. announced that Mark Eisner, M.D., M.P.H., will step down from his position as Executive Vice President and Chief Medical Officer. Dr. Eisner's departure is scheduled to be effective as of April 24, 2026. The company has formally initiated a search process to identify and appoint a successor for the Chief Medical Officer role. The filing, dated April 10, 2026, was signed by Marianne De Backer, the company's President and Chief Executive Officer. No specific reason for the departure was provided in the report, and no interim replacement was named at the time of the filing. Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.